Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

Zymeworks outlined a partnering-focused research strategy and presented updated clinical data for ZW191, its antibody-drug conjugate for platinum-resistant ovarian cancer; the article provides no efficacy figures. The company also discussed its recently announced collaboration with Roche on ZW209, a DLL3-targeting T-cell engager.